Last updated: 2026-09-14 10:43:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Pliant Therapeutics, Inc. (PLRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalization of $72.45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.02 to $1.95. This page covers its latest market performance, valuation, price trends and company information.
$72.45M | |
$1.17 | |
$43.92 | |
$1.02 | |
$1.17 | |
-- | |
493.60K | |
-- | |
$1.95 | |
$1.02 | |
-- | |
-- |
Pliant Therapeutics, Inc. (PLRX) is trading at $1.17 in pre-market trading as of 2026-09-14 09:11:00, unchanged from the previous close of $1.17
Pre-market trading shows how investors are pricing PLRX before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Pliant Therapeutics, Inc. (PLRX) moved from $1.16 to $1.17, representing a gain of 0.86% ($0.01).
The stock traded between $1.11 and $1.19 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 457.88 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 16.1%
PLRX is currently trading at $1.17, placing it 16.1% of the way from its 52-week low of $1.02 to its 52-week high of $1.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 49 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pliant Therapeutics, Inc. (PLRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.